Street Calls of the Week
Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary at Twist Bioscience Corp (NASDAQ:TWST), sold 233 shares of common stock on September 22, 2025, at a price of $27.56, for a total value of $6,421.
The sale was executed to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience’s equity incentive plans. Following the transaction, Cho directly owns 102,710 shares of Twist Bioscience. InvestingPro data shows the company maintains strong financial health with a current ratio of 3.9x and holds more cash than debt on its balance sheet. Discover more insights with InvestingPro’s comprehensive research report, available along with 6 additional ProTips for TWST.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this revenue growth, the company faced an adjusted EBITDA loss of $8 million, which nonetheless marked an improvement from the previous fiscal year. In a separate development, Twist Bioscience appointed Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake brings extensive leadership experience from her tenure at Vistaprint, where she significantly scaled the business.
Additionally, several analyst firms have recently adjusted their price targets for Twist Bioscience. JPMorgan lowered its price target to $25 from $33, maintaining an Underweight rating. TD Cowen also reduced its price target to $36 from $58, while keeping a Buy rating, citing changes in fiscal year 2025 guidance due to shifts in Next-Generation Sequencing revenue. Evercore ISI adjusted its price target to $46 from $50, maintaining an Outperform rating, following a strong performance in the next-generation sequencing segment and solid gross margin results. These developments highlight the mixed sentiment among analysts regarding Twist Bioscience’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.